NHS National Generics Pharmaceuticals - Dasatinib and Paliperidone Injection

Concepts

• pharmaceutical products
• nhs national generics pharmaceuticals
• paliperidone injection
• runcorn
• nhs national generic pharmaceuticals
• nhs national generics pharmaceuticals - dasatinib
• nhs national generic pharmaceuticals - dasatinib
• 01 - paliperidone injection
• total maximum duration of the framework agreement
• potential periods of call-offs

Location

Description

Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection Offer reference number: CM/PHG/22/5694 FIND A TENDER (FTS) Reference number Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/22/5694/00 - Dasatinib CESW 01/05/2023 - 30/04/2024 - (12 Months) LSNE 01/05/2023 - 30/04/2024 - (12 Months) NWLN 01/05/2023 - 30/04/2024 - (12 Months) CM/PHG/22/5694/01 - Paliperidone Injection: LSNE 01/05/2023 - 31/05/2024 (13 Months) NWLN 01/05/2023 - 31/01/2025 (21 months)

CPV Codes

• 33600000 - Pharmaceutical products

Indicators

• Contract is suitable for SMEs.

Other Information

Document No. 00 - Read Me First Document Document No. 00 - Read Me First Document.docx Document No. 01 - Invitation to offer covering letter Document No. 01 - Invitation to offer covering letter.docx Document No. 02 - Terms of offer Document No. 02 - Terms of offer.docx Document No. 05a(iv) CM_PHG_22_5694_01 Document No. 05a(iv) CM_PHG_22_5694_01.xml Document No. 05b - Selectt offer schedule instructions Document No. 05b - Selectt offer schedule instructions.docx Document No. 07b - Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines - Edition 5.1 September 2022 Document No. 07b - Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines - Edition 5.1 September 2022.pdf Document No. 08 - Confidential information schedule Document No. 08 - Confidential information schedule.xlsx Document No. 04a - Quality Assurance Process Document No. 04a - Quality Assurance Process.pdf Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements.pdf Document No. 05a(i) - Tender Product Listing and Usage - Dasatinib Document No. 05a(i) - Tender Product Listing and Usage - Dasatinib.xlsx Document No. 05a(ii) CM_PHG_22_5694_00 Document No. 05a(ii) CM_PHG_22_5694_00.xml Document No. 05a(iii) - Tender Product Listing and Usage - Paliperidone Document No. 05a(iii) - Tender Product Listing and Usage - Paliperidone.xlsx Document No. 06 - Form of offer Document No. 06 - Form of offer.docx Document No. 07a - Quality control technical sheet Document No. 07a - Quality control technical sheet.pdf Document No. 03 - Framework Agreement and Terms and Conditions V1 Document No. 03 - Framework Agreement and Terms and Conditions V1.pdf